A first-in-human clinical trial led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has reported encouraging results for an enhanced form of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or treatment-resistant B-cell blood cancers. The phase I study, published in Blood Cancer Discovery, tested a cell product engineered to attack three different proteins found on malignant B cells while simultaneously deploying an additional signaling protein to amplify the immune attack. For a patient population that typically runs out of options after standard CAR T-cell therapy fails, the findings offer a potential path forward.
CAR T-cell therapy is one of the most significant advances in cancer medicine of the past decade. The process begins with the collection of T cells, the immune system’s primary cancer-killing soldiers, from a patient’s own blood. In the laboratory, those cells are genetically modified to express a chimeric antigen receptor, a synthetic molecule that allows the T cell to recognize a specific protein on the surface of cancer cells. Once infused back into the patient, the engineered cells multiply and launch a targeted assault on the tumor. The approach has produced high rates of remission in B-cell blood cancers, a category that accounts for roughly half of all blood cancers and includes lymphomas and certain leukemias.
Despite that success, a major weakness has limited the durability of the treatment. Many patients relapse after CAR T-cell therapy, often within the first year, leaving them with few remaining treatment options. One reason is that the therapy usually targets a single protein, CD19, which plays a central role in B-cell blood cancers. Cancer cells can survive the initial attack by losing or reducing expression of that single target, a phenomenon known as antigen escape. Building on earlier animal studies conducted at other institutions, the Ohio State team designed a therapy that targets three proteins at once: CD19, CD20 and CD22. By forcing the cancer to evade three distinct targets simultaneously, the trispecific construct is intended to make escape far more difficult.
The second innovation in the trial was the use of OX40, an immune costimulatory protein, to strengthen the activity of the engineered cells. According to Sumithira Vasu, MD, professor of hematology and a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, who served as the study’s first and corresponding author, this was the first time a CAR T-cell clinical trial used OX40 to enhance the process and improve tumor death. Costimulatory signals such as OX40 act like an accelerator for T cells, promoting their expansion, persistence and killing capacity after they encounter tumor cells. Vasu noted that results from the trial could lead to better therapeutic outcomes for patients who may have limited options after their B-cell blood cancer has returned or their therapy stopped working.
The trial also addressed a practical challenge that has long troubled the field: manufacturing time. Conventional CAR T-cell production can take weeks, during which aggressive cancers may progress and patients may deteriorate. The Ohio State team used a point-of-care manufacturing process that collected, prepared and returned the cells to the patient in just six days. Critically, the cells were infused fresh rather than frozen, a distinction that some researchers believe preserves the potency of the product. Lapo Alinari, MD, PhD, associate professor of hematology and lead senior co-author of the study, said it has been suggested that fresh cell infusions are preferable, and that the team was able to show the feasibility of rapid manufacturing time and infusion of fresh cells.
The clinical results supported that premise. Alinari reported that the rapid, fresh-cell approach produced meaningful clinical activity with minimal side effects in patients with B-cell non-Hodgkin lymphoma, and achieved remission in mantle cell lymphoma, follicular lymphoma and diffuse large B-cell lymphoma. These are distinct subtypes of B-cell malignancy with different biological behaviors, and achieving remissions across multiple subtypes suggests the trispecific strategy may have broad applicability. Equally important for an early-phase trial, the therapy was well tolerated, with patients experiencing minimal side effects, an encouraging safety signal for a technology that combines three tumor-targeting domains with an additional immune-boosting element.
Eighteen patients were enrolled in the study, with a median age of 64. Sixteen of them were treated with the OX40-enhanced CAR T-cell product. The patient population reflected the difficult reality of relapsed disease: all enrolled patients had previously received a median of three different types of therapy before receiving the enhanced cell therapy. In other words, these were heavily pretreated individuals whose cancers had already resisted multiple standard approaches, the very group in which new therapies are hardest to evaluate and for whom the unmet need is greatest.
The study was published in Blood Cancer Discovery, a peer-reviewed journal of the American Association for Cancer Research, with the article titled Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22. The research involved a broad team of investigators from Ohio State and Nationwide Children’s Hospital, reflecting the multidisciplinary effort required to move an engineered cell therapy from the laboratory bench to the bedside, including cell processing specialists, biostatisticians, and clinicians across hematology and oncology.
Senior co-author Marcos de Lima, MD, professor of hematology at Ohio State, cautioned that while the trial showed encouraging outcomes for patients with B-cell non-Hodgkin lymphoma treated with the enhanced CAR T-cells, more research in larger patient groups is needed. That caveat is standard and appropriate for a phase I study, which is primarily designed to establish safety and feasibility rather than to definitively measure efficacy. Larger trials will be required to confirm the remission rates, characterize the side-effect profile more completely, and determine whether the OX40 enhancement and trispecific targeting translate into longer-lasting remissions than current single-target products.
Nevertheless, the trial represents a notable step in the evolution of cellular immunotherapy. It combines three strategies that researchers have pursued independently, multi-antigen targeting to prevent immune escape, costimulatory enhancement to strengthen T-cell function, and rapid point-of-care manufacturing to deliver fresh cells before the disease can progress, into a single therapeutic platform. If subsequent studies validate these early findings, the approach could expand the reach of CAR T-cell therapy to patients who currently relapse after standard treatment, and the six-day manufacturing timeline could make this sophisticated form of personalized medicine faster and more accessible for the patients who need it most urgently.
Subject of Research: A first-in-human phase I trial of trispecific OX40-enhanced CAR T-cell therapy for relapsed B-cell blood cancers
Article Title: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers
Article References: Clinical trial shows positive results of enhanced CAR T-cell therapy for patients with B-cell blood cancers. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: CAR T-cell therapy, B-cell blood cancers, non-Hodgkin lymphoma, CD19, CD20, CD22, OX40, clinical trial, immunotherapy, cell manufacturing, Ohio State University, Blood Cancer Discovery
